Cancer Chemotherapy I: Hepatocellular Injury

Edmundo A. Rodriguez-Frias, William M. Lee

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Although hepatotoxicity is a frequent concern with all medications, chemotherapeutic agents are more often implicated in causing liver damage than most other drug classes. In many instances, these reactions are considered dose related because cytotoxic therapy directed at rapidly growing cancer cells may readily impact hepatocytes even though they are dividing more slowly. Because the stakes (remission of cancer) are high, so are the risks that the oncologist and the patient are willing to assume. The dose of many chemotherapeutic agents is limited by the toxic effects on the lungs, bone marrow, kidneys, and gastrointestinal system, including the liver. An awareness of the toxic potential of each chemotherapeutic agent is necessary before initiation of new oncologic treatments.

Original languageEnglish (US)
Pages (from-to)641-662
Number of pages22
JournalClinics in Liver Disease
Issue number3
StatePublished - Aug 2007

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Cancer Chemotherapy I: Hepatocellular Injury'. Together they form a unique fingerprint.

Cite this